ARCHIVES

House Measure Would Eliminate AHRQ, Rescind PCORI, Cut Outcomes Research, And Halt NIH’s Title 42 Hiring Program

This article is from The Cancer Letter archive.

Vol. 38 No. 29 | July 20, 2012

Download PDF Visit The Full Archive

Related Articles

Shubik Subcommittee Criticizes New Study Section, Asks NCI To Hire More Epidemiologists

December 5, 1975

GAO Decision Clears NCI to Deploy Medidata Rave Data Capture System

June 17, 2011

BRCA Status Can Guide Ovarian Cancer Treatment

April 25, 2008

In Brief: King ACCC President, Fleming President Elect; Wyngaarden Says He Doesn’t Oppose Panel

March 25, 1988

MIT Researcher Ingested P-32; NRC Investigating

October 27, 1995

The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken.

May 7, 2004